1.
Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.
2.
3.
4.
5.
6.
7.
Le medicament du mois. Combinaison fixe ezetimibe-rosuvastatine (Myrosor(R)). ; Ezetimibe-rosuvastatin fixed-dose combination (Myrosor(R))
Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.
Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2. ; Sitagliptine (Januvia): incretin...
Les nouvelles recommandations Europeennes pour le traitement des dyslipidemies en prevention cardiovasculaire. ; New European guidelines for the management of dyslipidaemia in card...
L'etude clinique du mois. L'etude ADOPT: quel antidiabetique oral initier chez le patient diabetique de type 2? ; ADOPT study: which first-line glucose-lowering oral medication in...
Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.
Le medicament du mois. Bydureon: premier agoniste des recepteurs du GLP-1 en une injection hebdomadaire (exenatide a liberation prolongee). ; Bydureon: first once weekly GLP-1 rece...
Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study
8.
La sitagliptine dans le traitement du diabete de type 2: le point, cinq ans apres sa commercialisation. ; Sitagliptin in the treatment of type 2 diabetes: insights five years after...